Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug Interaction Study of CHF10196 With Dabigatran and Rosuvastatin in Healthy Male Participants
NCT07744386Phase 1Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florensocatib, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at 96 hours, Area Under the Curve from Time Zero to Infinity at 96 hours and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
florensocatib
Beyond the preview
Go deeper on NCT07744386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744386.